It’s good for Lynch and MSI generally, I think. But a key step is to bring this kind of result to those who are not in the small group that current immunotherapy targets.
I would add that this is one of the strategic dilemmas CRC patients face in the current environment. The current effective therapies for MSS can have decidedly negative effects on the immune system, including some that are permanent or semi-permanent. While the proper balance of anti-cancer and immunosuppressive effects is often achieved, I am mindful of the rapid advances in the immunotherapy field. It is very important to focus on exercise, diet, and overall health for these reasons. Not only does a healthy immune system help protect against progression generally, but it also keeps patients in the group would could derive benefit from what may be very rapid advances in this area in the near future.
I know it’s darn hard, but I am working diligently to improve diet for these reasons: maximizing plant proteins, minimizing sugar, minimizing carbs (more sugar), no more mammals for dinner, and no (or nearly no) alcohol. The exercise is fun, so that’s easy. May not matter in the end, but it just might, at that.
7/19: Rectal cancer: Staged IIIA, T2N1M0
approx 4.25 cm, low/mid rectum, mod. well diff.; lung micronodule
8/22 -10/14 4 rounds FOLFOX neoadjuvant, 3 w/Oxiplatin (side effects/reduced 70-75%)
neoadjuvant chemorad 11/19
4 rounds FOLFOX July-August 2020
ncCR 10/20; biopsies neg
TAE 11/20, tumor cells removed
Chest CT 3/30/21 small growth in 2 nodules (3 and 5mm)
VATS 12/8/21 sub-pleural met 7mm.
SBRT nodule 1/22
CT 3/22: Clear
Thoracic CT 5/19/22 Clear
6/20/22 TAE rectal polyp benign